“Determining whether [a 50.4% increase in the retail prices for 98 specialty drugs from 2004 through December 2009] was a reasonable rate of price inflation or not needs to be established by the manufacturers, something they have not done a very good job at to date. The particularly high specialty price growth during this time shows the oft-mentioned arrogance of many biopharm companies who seemed out of touch with market trends and attitudes.”
— F. Randy Vogenberg, Ph.D., a principal with the Institute for Integrated Healthcare, told AIS’s Specialty Pharmacy News.
At Medicare is Simple, we look to educate and enable you to choose among Medicare plans to help find the policy that may best fit your needs. Get free quotes using our advanced quoting technology. HealthCare Reform is also a hot topic of interest to people of all ages, and we look to keep you updated on the issues relevant to learning more. Medicare Is Simple 800-442-4915
No comments:
Post a Comment